RNDr. Pavel Krejčí, Ph.D.
Head of the research group, Pavel Krejčí Research Group
office: bldg. A19/231a
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 5395 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 126
2012
-
Bent Bone Dysplasia-FGFR2 type, a Distinct Skeletal Disorder, Has Deficient Canonical FGF Signaling
The American Journal of Human Genetics, year: 2012, volume: 90, edition: 3, DOI
-
Exome Sequencing Identifies PDE4D mutations in Acrodysostosis
The American Journal of Human Genetics, year: 2012, volume: 90, edition: 4, DOI
-
p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice.
The journal of clinical investigation, year: 2012, volume: 122, edition: 6, DOI
-
Receptor tyrosine kinases activate canonical WNT/beta catenin signaling via MAP kinase/LRP6 pathway and direct beta-Catenin phosphorylation
Plos One, year: 2012, volume: 7, edition: 4, DOI
-
Sixteen years and counting: the current understanding of fibroblast growth factorreceptor 3 (FGFR3) signaling in skeletal dysplasias.
Human Mutation, year: 2012, volume: 33, edition: 1, DOI
-
Způsob stanovení závažnosti a prognózy B-buněčné chronické lymfocytární leukémie
Publisher: , state: Czech Republic, patent's number: 303555, year: 2012
2011
-
Mitogen-Activated Protein Kinases Promote WNT/beta-Catenin Signaling via Phosphorylation of LRP6
Molecular and cellular biology, year: 2011, volume: 31, edition: 1, DOI
-
Post-translational modifications regulate signalling by Ror1
Acta Physiologica, year: 2011, volume: 203, edition: 3, DOI
-
Sequential activation and inactivation of dishevelled in the Wnt/{beta}-catenin pathway by casein kinases.
Journal of Biological Chemistry, year: 2011, volume: 286, edition: 12, DOI
-
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting insuppression of human myeloma cell growth and survival.
Leukemia, year: 2011, volume: 25, edition: 3, DOI